Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

被引：0

作者：

Even, C. ^{[1
]}

Bernard-Tessier, A. ^{[2
]}

Texier, M. ^{[3
]}

Said, O. Ben ^{[4
]}

Iacob, M. ^{[5
]}

Daste, A. ^{[6
]}

Fayette, J. ^{[7
]}

Zanetta, S. ^{[8
]}

Lefebvre, G. ^{[9
]}

Vinches, M. ^{[10
]}

Johnson, A. C. ^{[11
]}

Le Moal, L. Bozec ^{[12
]}

Saada, E. B. ^{[13
]}

Jallut, I. ^{[14
]}

Garic, F. ^{[15
]}

Monard, L. ^{[16
]}

Bourhis, J. ^{[17
]}

Guigay, J. ^{[18
]}

Auperin, A. ^{[19
]}

Ammari, S. ^{[20
]}

机构：

[1] Inst Gustave Roussy, Head & Neck Oncol Dept, Villejuif, France

[2] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[3] Inst Gustave Roussy, Biostat & Epidemiol, Villejuif, France

[4] Gustave Roussy, Radiol, Canc Campus, Villejuif, France

[5] IRO Reg Inst Oncol, Med Oncol Dept, Villejuif, France

[6] CHU Bordeaux, Med Oncol Dept, Hop St Andre, Bordeaux, France

[7] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[8] Ctr Georges Francois Leclerc Dijon, Med Oncol Dept, Dijon, France

[9] Ctr Oscar Lambret, Med Oncol Dept, Lille, France

[10] ICM Inst Canc Montpellier, Med Oncol Dept, Montpellier, France

[11] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[12] Hop Rene Huguenin, Inst Curie, Med Oncol Dept, St Cloud, France

[13] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France

[14] Unicancer, R&D, Paris, France

[15] Unicancer, Paris, France

[16] Unicancer, UCGI R&D, Paris, France

[17] CHU Vaudois, Radiat Oncol Dept, UNIL CHUV, Lausanne, Switzerland

[18] Ctr Anticancer Antoine Lacassagne, Med Oncol Dept, Nice, France

[19] Gustave Roussy, Biostat & Epidemiol, Canc Campus, Villejuif, France

[20] Gustave Roussy, Med Oncol Dept, Canc Campus, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.799

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

675P

引用

页码：S851 / S851

页数：1

共 50 条

[11] TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis
Even, C.
Daste, A.
Fayette, J.
Lefebvre, G.
Saada-Bouzid, E.
Zanetta, S.
Toullec, C.
Cupissol, D.
Salas, S.
Kaminski, M. C.
Johnson, A. C.
Vauleon, E.
Le Tourneau, C.
Sire, C.
Prevost, A.
Jallut, I.
Bourhis, J.
Guigay, J.
Auperin, A.
Texier, M.
ANNALS OF ONCOLOGY, 2020, 31 : S662 - S662
[12] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Bauman, J. E.
ANNALS OF ONCOLOGY, 2018, 29
[13] Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival.
Siano, Marco
Espeli, Vittoria
Desax, Marie-Claire
Broglie, Martina Anja
Joerger, Markus
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[14] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Licitra, Lisa F.
Haddad, Robert I.
Even, Caroline
Tahara, Makoto
Dvorkin, Mikhail
Ciuleanu, Tudor-Eliade
Clement, Paul M.
Mesia, Ricard
Kutukova, Svetlana I.
Zholudeva, Lyubov
Daste, Amaury
Caballero, Javier Daroqui
Keam, Bhumsuk
Vynnychenko, Ihor
Lafond, Cedrik
Shetty, Jagdish
Morsli, Nassim
Mann, Helen
Fayette, Jerome
Ferris, Robert L.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[15] Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
Mirallas, O.
Marmolejo Castaneda, D. H.
Illescas, D. G.
Gomez-Puerto, D.
Berche, R.
Calvo, A. H.
Vieito Villar, M.
Lorini, L.
Navarro, V.
Assaf Pastrana, J. D.
Saavedra, O.
Alonso, G.
Aguilar Izquierdo, S.
Bescos, C.
Lorente, J.
Giralt, J.
Dienstmann, R.
Garralda, E.
Felip, E.
Brana, I.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S857
[16] A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy
Zandberg, D. P.
Chen, J.
Tatsuoka, C.
Normolle, D. P.
Ohr, J.
Isett, B.
Rahman, Z.
Fenton, M.
Gooding, W.
Vujanovic, L.
Bao, R.
Marsh, C.
Seastone, D.
Gorantla, V.
Pabla, S.
Conroy, J.
Ferris, R. L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E4 - E4
[17] Sequential Treatment Use in Clinical Practice for US Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Zheng, D.
Black, C. M.
Hair, G. M.
Bidadi, B.
Lerman, N.
Ai, L.
Zion, A.
Zou, L.
Gao, W.
Hanna, G. J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E34
[18] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
Hernando-Calvo, A.
Mirallas, O.
Marmolejo, D.
Felip, E.
Villacampa Javierre, G.
Garralda, E.
Gutierrez, R.
Feliu, B.
Martinez, S.
Dienstmann, R.
Brana, I.
ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
[19] Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study
Bernal, M. Oliva
Lien, S.
Wang, B. X.
Yang, S. C.
Spreafico, A.
Jang, R.
Elston, S.
Jennings, S.
Jiang, H.
Haibe-Kains, B.
Pugh, T.
Ohashi, P.
Siu, L. L.
Hansen, A.
ANNALS OF ONCOLOGY, 2018, 29
[20] Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients
Taylor, K.
Zou, J.
Burgener, J.
Zhao, E.
Torti, D.
Oliva, M.
Spreafico, A.
Hansen, A. R.
Jang, R.
McDade, S. S.
Coyle, V. M.
Lawler, M.
Elimova, E.
Bratman, S. V.
Siu, L. L.
ANNALS OF ONCOLOGY, 2021, 32 : S796 - S797

← 1 2 3 4 5 →